Technology | April 09, 2026
Halozyme strikes global deal with Vertex to expand Hypercon drug delivery technology
The deal gives Vertex access to Halozyme’s Hypercon technology for up to three drug targets
The deal gives Vertex access to Halozyme’s Hypercon technology for up to three drug targets
TriNetX will provide Regeneron secure, licensed access to de-identified health data from its global network of health system partners
Biopharma companies face persistent hurdles in cell line development, including long timelines, low yields, and high failure rates for novel molecules
The acquisition adds VYKAT XR (diazoxide choline), the first FDA-approved therapy for hyperphagia in Prader-Willi syndrome (PWS), a rare genetic disorder, to Neurocrine’s portfolio
The new capital is expected to fund the company through 2029
Interchangeable biosimilars to Prolia and Xgeva target osteoporosis and cancer-related bone complications in a $5 billion U.S. market
Under the collaboration, Symeres will test Ambagon’s newly designed molecular glues using in vitro assays and mechanistic studies
Multi-year CDMO partnership combines AI-led virtual development, precision chemistry and GMP manufacturing to accelerate five high-science APIs across regulated markets
India’s first prospective study finds molecular testing improved diagnostic clarity in 50% of complex sarcoma cases
Recognition across subsidiaries and geographies highlights pharma major’s focus on inclusive culture, employee experience, and global workforce development
Subscribe To Our Newsletter & Stay Updated
